key: cord-0990955-mgeqe4ur
authors: Mantha, Olivier L.; Flamein, Florence; Turner, Mark; Fernandes, Ricardo M.; Hankard, Regis
title: Early Impact of SARS-CoV-2 on Pediatric Clinical Research: A Pan-European and Canadian Snapshot in Time
date: 2021-08-23
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.08.028
sha: a15cd21e5039efcf1776ebf6cf282b0ee45deb6b
doc_id: 990955
cord_uid: mgeqe4ur

OBJECTIVE: To capture the early effects of the SARS-CoV-2 pandemic on pediatric clinical research. STUDY DESIGN: Pediatric clinical research networks from 20 countries and 50 of their affiliated research sites completed two surveys over one month from early May to early June 2020. Networks liaised with their affiliated sites and contributed to the interpretation of results through pan-European group discussions. Based on SARS-CoV-2 first detection dates, countries formed one early and one late detecting cluster. We tested the hypothesis that this clustering influenced clinical research. RESULTS: Research sites were first impacted by the pandemic in mid-March 2020 (03/16 ±10 days, the same date as lockdown initiation, P = .99). From first impact up until early June, site initiation and feasibility analysis processes were affected for ˃50% of the sites. Staff were redirected to COVID-19 research for 44% of the sites and 75.5% of sites were involved in pediatric COVID-19 research (only 6.3% reported COVID cases in their other pediatric trials). Mitigations were used, but differently between the early and late detecting country clusters and between countries with and without a pediatric COVID-19 research taskforce. Positive effects include the development of teleworking capacities. CONCLUSIONS: Through this collaborative effort from pediatric research networks, we found that pediatric trials were affected and conducted with a range of unequally applied mitigations across countries during the pandemic. The global impact might be greater than captured. In a context where clinical research is increasingly multinational, this report reveals the importance of collaboration between National Networks.

The SARS-CoV-2 pandemic impacted healthcare in many ways. Yet the impact on clinical research 1,2 is unclear, even more so that different medical specialties may have been impacted differently. Although there have been, for instance, reports in oncology [3] [4] [5] (including pediatric oncology 6, 7 ) there have been none of such extent for the broad field of pediatrics, where recent work includes calls to mitigate the impact on ongoing and future trials. 8, 9 This is perhaps because children are less directly impacted by the COVID-19 disease. Nonetheless, pediatric clinical research organization has been greatly affected by the pandemic. European pediatric clinical research National Networks ( Table I ; available at www.jpeds.com) are part of conect4children, a pan-European network aiming at facilitating the development of pediatric therapies (https://conect4children.org/). 10, 11 Like other organizations, National Networks were facing the unknown when the SARS-CoV-2 pandemic arrived. This report is a joint effort from 19 European National Networks and 2 Canadian networks to assess the impact on pediatric clinical research. Such an effort of capturing and giving meaning to information is a learning process for the global pediatric clinical research network and contributes to shaping its organization.

This study aims to assess the early impact of the SARS-CoV-2 pandemic on the conduct and organization of pediatric clinical research on a multinational scale. Data were gathered from research centers across geographical Europe and in Canada and analyzed and interpreted collaboratively to comprehensively depict the situation. After observing that the countries formed two clusters differing on the timing of the pandemic and potentially on national attitudes to J o u r n a l P r e -p r o o f managing it, we tested the hypothesis that clinical research was more impacted where the virus has been present for longer. We also sought further evidence of inconsistency between countries in the mitigations used to ensure trial continuity.

This study was conducted in 20 countries. Information on the National Networks involved (name and number of affiliated research sites) are available in Table 1 . A data collection phase using surveys was followed by an interpretation phase in which the data were analyzed and reviewed collaboratively by the National Networks to provide a global perspective.

Two web-based surveys (Appendix 2; available at www.jpeds.com) were designed by the French pediatric clinical research network (PEDSTART) ( Table 1 ) and administered in Google Forms. A first survey was developed and used to identify at the national and National Network level: (1) the composition of the National Networks in terms of the number of affiliated research centers, (2) how countries were currently affected by the pandemic and the measures undertaken at the national, regional, and network levels, and (3) the impact on pediatric clinical research networks' activities. A second site-focused web-based survey then had to be disseminated by email from the networks to their affiliated research sites. This latter survey was used to evaluate directly the impact of the pandemic on pediatric clinical research at the research site level.

After being pilot tested, the surveys were disseminated by email to the National Networks on May 5 th , 2020. National Networks and associated research sites initially had 10 days from May 5 th to May 15 th , 2020 to complete the online surveys. More time was then allotted to maximize the number of respondents resulting in a last submission of the site survey on June 11 th (average date of site survey completion is May 15 ±9 days). No answers were mandatory except contact details.

Respondents could modify their responses by filling the questionnaire in again and sending an email notification.

The data gathered during this initiative were curated by the French National Network (PEDSTART). Raw data were first presented to the other National Networks and subsequent dedicated pan-European group discussions were organized. Pan-European group discussions with National Networks were used to refine data interpretation by considering cultural, semantic, and other differences between countries. These discussions, in groups of around 10 National Network representatives, allowed for a multi-national interpretation of the results.

Dates were converted to number of days elapsed since January 1 st , 2020 for graphical representation and statistical analyses. Country clusters based on the date a 1 st case of SARS-CoV-2 infection was detected were confirmed using Bayesian information criterion and optimal univariate k-means clustering. 12 Differences between clusters not related to clinical research are shown in Table 2 (available at www.jpeds.com). Non-binary survey questions were collapsed to binary outcomes for statistical analyses. Differences between clusters and between countries with or without a dedicated pediatric COVID-19 research taskforce were analyzed using t-tests and the Fisher exact test for proportions. A significance level of 0.05 was used and numerical data are presented as mean ± SD. J o u r n a l P r e -p r o o f

The 21 networks involved in this study (Table 1) Table 1 ). Figure 1 , A shows the number of pediatric clinical research sites which contributed to this study per National Network. There was an average of 3 research sites per National Network. Figure 1 , B shows how many pediatric clinical studies the sites reported to be undertaking before the SARS-CoV-2 outbreak.

Countries were impacted and responded differently according to their pediatric clinical research networks. Table 2 ). The early detecting country cluster had a longer delay before going into lockdown (p˂0.001)( Figure 2 , A), and clusters did not differ with respect to lockdown initiation date and other metrics not related to pediatric research except population (Table 2 ) Only 6 countries (5 in Figure 2 and Czechia) reported that a pediatric COVID-19 taskforce was in place to help in cataloging current initiatives and predicting consequences. Only German, Canadian, Polish, and British networks reported regional differences in the measures J o u r n a l P r e -p r o o f taken at this stage of the pandemic. National Networks reported that recommendations for pediatric clinical research during the pandemic were issued by national societies for 39% (7/18) of countries.

A total of 50 pediatric clinical research sites ( Figure 1 ) were involved in this study. The moment when the outbreak started affecting each pediatric research sites activity is plotted in (Table 2) , not supporting the hypothesis that clinical research was impacted differently in these countries. Table 3 shows COVID-19 research at sites, how pediatric clinical research was impacted, and the mitigations used to ensure continuity of clinical trials during the pandemic. There was again no difference between the early and late detecting country clusters and between countries with and without a taskforce of the impact on clinical research and of COVID-19 research at sites. Close to half (44%) of the research sites reported that some of their staff were redirected to COVID-19 research projects. Although 75.5% of the sites were involved in pediatric COVID-19 research projects, only 6.3% reported SARS-CoV-2 infections in children participating in non-COVID clinical trials. Sixty-six percent of the sites involved in this study reported that clinical research sites initiation visits were cancelled and 54.3% reported that the clinical trial feasibility analysis J o u r n a l P r e -p r o o f process was affected. There were reports of studies being temporarily or permanently discontinued.

Less clinical research visits were performed during the pandemic for 36.7% of sites, a figure perhaps lowered by the involvement of some sites in COVID projects. Figure 3 shows the documented effect of the pandemic on pediatric clinical research visits at a French site (one with more than 40 ongoing studies [ Figure 1 , B]). As compared with 2019, there was an abrupt decrease in the number of visits performed during the first 2020 lockdown and an abrupt overshoot afterwards (Figure 3 ), resulting in a similar total yearly number of visits performed.

In this context, mitigations were used by research sites, but inconsistently between countries.

Some clinical research visits were reported to be replaced by phone calls for 85.7% of the surveyed sites and by home nurse interventions for 22.4% of them (Table 3) . Other procedures were put in place to ensure continuity of care and safety of enrolled patients and included: sending study drug treatment to the patient's home, performing biological safety assessments at the patient's home or at a nearby laboratory, and administering questionnaires and standard tests via telephone or videoconference (Table 3 ). There was no differences between the early and late detecting country clusters and between countries with and without a taskforce on the mitigations used except for sending study drug treatment to the patient's home that occurred more in the early detecting cluster (p<0.01) and in countries with a taskforce, with a difference close to being statistically significant for the latter (p = 0.06)( Table 3) (Table 3 ). This is in line with site initiation visits cancellation reported by the Innovative Therapies for Children with Cancer consortium. 6 Twenty countries were involved ( Table 1 ). The average participation rate of 25% of National Networks affiliated research sites (Figure 1, A) is encouraging for follow-up studies. The dataset gathered suggests the different countries were initially impacted at different rates by the pandemic (Figure 2 , A and Table 2 ). Other non-pediatric reports already noted country-specific impacts of the pandemic on clinical research. 3, 13 For instance, at the time a previous survey was administered, there was a smaller effect on enrollment in oncology trials in Asia compared with Europe and the United States. 3 This reinforces the dynamic nature of the pandemic and that these differences between countries at one point in time could be the main caveat of the current analysis.

Yet, we found no difference between the early and late detecting country clusters and between countries with a without a taskforce on the impact on clinical research. The 28 days difference before lockdown initiation between the early and late detecting country clusters ( Table 2 ) could reflect national attitudes to managing the pandemic. To what extent this clustering is meaningful, besides reflecting population differences (Table 2) , is uncertain, given that the alternative of using J o u r n a l P r e -p r o o f 1 detected case per million inhabitants 14 does not cluster countries in a similar way. Taken together, our data suggests that what impacts clinical research, and did not differ much here between countries ( Figure 2 and Table 2 ), is the timing of containment measures.

The impact of the pandemic was on average first felt by pediatric clinical research sites ( Figure 1 ) in mid-March 2020 (Figure 2, B) . Staff were mobilized to COVID-19 research in some but not all sites (Table 3) . A substantial proportion of surveyed sites (76%) was involved in pediatric COVID-19 research as well. Non-COVID-19 studies that were perturbed and reorganized during the first lockdown were not disturbed much by SARS-CoV-2 infections in children. In parallel, it was reported that the lockdown appreciably reduced pediatric admissions and visits for viral and nonviral infections. 15 Main pandemic hurdles for pediatric clinical research concerned the feasibility and site initiation processes for trials that had not yet started and patient visits to research centers for the ongoing trials (Table 3 ). This is corroborated by more granular data from a French site showing patient visits cancellations during the early stage of the pandemic and the lockdown and a subsequent overshoot with more visits than usual being performed after restrictive measures were lifted ( Figure 3 ). More data to confirm whether this is generalizable are required, but this is in line with the decrease in new subject enrollment in many therapeutic areas in Europe and Asia reported for the same period. 13 Sites' involvement in COVID-19 studies might explain why few sites reported performing less patients visits on site (Table 3) .

Still, consistent with some of the special considerations formulated elsewhere 13 , research sites applied mitigations to ensure continuity of clinical trials, but heterogeneously between countries (Table 3 and Table 4 ). We found that the early detecting country cluster and countries with a pediatric COVID-19 taskforce were more prone to sending study drugs to the patient's home.

The early detecting country cluster being ~3 times as populous ( Table 2 ), perhaps that this J o u r n a l P r e -p r o o f mitigation is more conceivable in bigger countries. Understanding the underlying reason could help broadening its future use. Although mitigations ensured continuity of clinical trials during the pandemic, questions could also be raised about the observance of a medicinal product sent to a patient's home and about the impact of visits performed remotely (as opposed to face-to-face) on the quality of clinical research. It could be argued that the latter are less reliable for gathering some types of data.

Due to less travel, teleworking and teleconferencing lowered transport and maintenance costs and result in decreased environmental impact. Meetings were easier to organize. However, the involvement of networks stakeholders is difficult to maintain by teleconference. It is also harder for newcomers to find their place (Table 4 ) and teleconferences do not allow for potentially important networking and exchange of ideas as in face-to-face meetings.

We acknowledge that limitations of the current study include the small sample size in terms of number of research sites within some National Networks and differences between countries at the time of the survey, as well as potential semantic and cultural differences affecting interpretation of survey questions. The involvement of pediatric clinical research National Networks (Table 1) should have helped minimize the impact of the latter. The participation rate is lowered by National Networks for which no affiliated site contributed (Networks in Switzerland, Finland, Germany, and Norway). Networks in UK and Poland were excluded from the calculation because they did not disseminate the survey to their affiliated sites. The British network decided not to distribute the survey considering the level of COVID research that was ongoing at the time of the survey and the pressures on the sites to deliver key COVID research. Canada was also excluded because there is no official National Network there. Two networks from Canada, rather than 1 elsewhere, contributed to the current study (Table 1 ). There was, however, only 1 research site from Canada J o u r n a l P r e -p r o o f involved (Figure 1, A) . The assumption that each site survey respondent represents what National Networks consider a distinct research site could also bias our estimate of the participation rate.

Compared with lockdown initiation dates reported elsewhere 14 , dates reported by the National Networks differ slightly for some countries.

COVID-19 brought unity across and within countries in pediatric clinical research. We shared practices, which allowed us to pinpoint potential areas of improvement. With this study, we show how pediatric clinical trials were impacted and reorganized in the early stage of the outbreak, a major finding being that a range of mitigations was used but were applied inconsistently in different countries. This crisis allowed us to develop and reflect on different ways of working.

Above all, in a context where clinical research is increasingly multinational, with both academic and industrial stakeholders, this work shows the value of collaboration between National Networks. J o u r n a l P r e -p r o o f Table 3 . COVID-19 research at sites, impact on pediatric clinical research and mitigations used to ensure continuity of clinical trials (% of sites (fraction of sites)).

EDC, early detecting cluster (n = 7 countries); LCD, late detecting cluster (n = 11 countries). *% of countries in in Figure 1 are also shown in parentheses for mitigations.  In what sense may this crisis help to move forward areas of activity or ways of working?

 Do you think the network of national networks (NNN), as a group, may have an impact on how the paediatric clinical research will be managed post-pandemic?

 Any other comments

The following questions apply to European countries only.

J o u r n a l P r e -p r o o f

Preserving Clinical Trial Integrity During the Coronavirus Pandemic

US Food and Drug Administration: FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: Guidance for industry, investigators, and institutional

Impact of COVID-19 on oncology clinical trials

Early impact of COVID-19 on the conduct of oncology clinical trials and long-term opportunities for transformation: Findings from an

The impact of COVID-19 on clinical trial execution at the dana-farber cancer Institute

Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium

Challenges in early phase clinical trials for childhood cancer during the COVID-19 pandemic: a report from the new agents group of the Spanish Society of Paediatric Haematology and Oncology (SEHOP)

Impact of COVID-19 on pediatric clinical research in France

Considerations and future directions for conducting clinical research with pediatric populations during the COVID-19 pandemic

European research networks to facilitate drug research in children

The conect4children (c4c) Consortium: Potential for Improving European Clinical Research into Medicines for Children

Ckmeans. 1d. dp: optimal k-means clustering in one dimension by dynamic programming

Impact of COVID-19 on clinical trials and clinical research: A systematic review

The lockdown effect: A counterfactual for Sweden. CEPR Discussion Paper 14744

COVID-19 pandemic: Impact caused by school closure and national lockdown on pediatric visits and Impact of the pandemic on Paediatric Clinical Research National Networks Scope: to describe the impact of the COVID-19 pandemic on elements of paediatric Clinical Research we can act upon

Through this collaborative effort from pediatric research networks, we found that pediatric trials were affected and conducted with a range of unequally applied mitigations across countries during the pandemic. The global impact might be greater than captured. In a context where clinical research is increasingly multinational, this report reveals the importance of collaboration between National Networks. J o u r n a l P r e -p r o o f

 Email address:  Organization name:  Country:  How many sites do you coordinate as a national network?  Is your country in lockdown? Yes No  Date of initiation of lockdown:  Did the government of your country engage other measures than confinement  and when?  Are measures against COVID-19 the same in all regions of your country (please  explain if the answer is no)?  When was the first patient confirmed for COVID-19 in your country?  Any additional information on governmental measures taken in your country?

 Did you organize a COVID-19 research "task force" within your network and with sites? (task force being a group that is dedicated to cataloguing current initiatives and predicting consequences) J o u r n a l P r e -p r o o f 

Concerns that the absence of face-to-face interactions combined with a high rate of staff turnover would weaken the networks and affect the integration of new members

Other mitigations than reported in Table 3 :